An experimental study on the ameliorating effect of terazosin on whole-brain irradiation-induced cognitive dysfunction / 中华放射肿瘤学杂志

Objective:To verify the protective effect of terazosin on cognitive function of rats after whole-brain irradiation (WBI) and to investigate its mechanism.Methods:A total of 64 1-month-old male SD rats were randomly divided into the untreated control group, terazosin group, irradiation group and irradiation plus terazosin group (combination group). WBI was administered at a single dose of 20 Gy in the irradiation and combination groups. The open field test and the Morris water maze (MWM) test were used to evaluate the effect of terazosin on cognitive function after WBI.Starting from the three aspects of juvenile neuron apoptosis, neurogenesis disorderand microglia activation, the possible cellular mechanism wasassayed by double-label immunofluorescence staining for BrdU (bromodeoxyuridine) / NeuN, DCX(Doublecortin) / Caspase-3 and single-label immunofluorescence staining for Iba-1 (ionized calcium binding adaptor molecule-1).Results:Terazosin intervention improved the short-term memory retention of irradiated rats ( P=0.032). After terazosin treatment, the number of DCX + cells in the combination groupwas increased by approximately 35% compared with that in the irradiation group ( P=0.038). The number of BrdU +/NeuN + cells in the combination group was increased by approximately 15% than that in the irradiation group ( P>0.05). The number of Iba-1 + cells in the irradiation plus terazosin group was decreased by 49% compared with that in the irradiation group ( P=0.036). Conclusion:Terazosin may reduce the hippocampal juvenile neuron loss and inhibit neuroinflammation via microglia activation, which can alleviate WBI-induced cognitive dysfunction to a certain extent.

Determination of Related Substance in Terazosin Hydrochloride Tablets by HPLC and Principal Component Self-control with Correction Factor / 中国药房

OBJECTIVE： To establish the method for the content determination of related substance in Terazosin hydrochloride tablets. METHODS： HPLC and principal component self-control with correction factor were adopted. The determination was performed on Agilent Zorbax Eclipse XDB C18 column with mobile phase consisted of acetonitrile-perchloric acid solution （20 ∶ 80， V/V） at the flow rate of 1.0 mL/min. The detection wavelength was set at 246 nm， and sample size was 20 μL. The column temperature was 50 ℃. The linear equations of terazosin hydrochloride， impurity A， B， C were drawn. The correction factors of each impurity related to terazosin hydrochloride were calculated by slope， and relative retention time was used to determine the position of impurities. The contents of impurity A， B and C in 3 batches of Terazosin hydrochloride tablets were determined and compared with the results of impurity control method. RESULTS： The relative retention time of impurity A， B， C was 0.39， 0.74， 2.77， respectively； the linear range of them were 0.25-3.0 μg/mL， respectively. The correction factors were 0.75， 1.09， 0.84， respectively. The detection limits were 0.35， 0.51， 0.43 ng， and the limits of quantification were 0.70， 1.02， 0.86 ng， respectively. The contents of impurity A， B and C in 3 batches of Terazosin hydrochloride tablets were 0.11％-0.13％， 0.03％ and 0.09％-0.12％； impurity B did not detected. The results are consistent with the determination of impurity control method. CONCLUSIONS： The method is simple， rapid and accurate for the content determination of related substances A， B， C in Terazosin hydrochloride tablets.

Bioequivalence of terazosin hydrochloride tablets in healthy volunteers / 中国药学杂志

OBJECTIVE: To evaluate the bioequivalence of test and reference preparation of terazosin hydrochloride tablets in healthy malevolunteers. METHODS: This is openrandom and two-way crossover clinical trial involved 18 healthy male subjects. The volunteers were randomly divided into two groups. They were given single oral dose of test and reference preparation of terazosin hydrochloride tablets (each 2 mg). The plasma concentrations of terazosin were determined by LC-MS /MS. Pharmacokinetic parameters were obtained using DAS2.0 program. RESULTS: The main pharmacokinetic parameters of terazosin hydrochloride tablets test and reference preparation were as follows: tmax were 1.00(0.25, 2.00) h and 0.75(0.50, 4.00) h, ρmax were and (49.72 ± 9.86) and (61.66 ± 18.37) ng•mL -1, AUC0-t were ( 516.35 ± 107. 33) and (616.58 ± 118.48) ng•h•mL -1, AUC0-∞ were (532.62 ± 112.42) and (634.99 ± 122.49) ng•h•mL -1 respectively. The relative bioavailability was (100.17 ± 13.92) %. And 90% confidence limit of test preparation of the logarithmic transformed parameters AUC0-t and ρmax were in 93.8% - 105.1% and 88.3%-108.4% compared with reference preparation, respectively. No serious adverse events were observed during the trials. CONCLUSION: Two kinds of terazosin hydrochloride tablets are bioequivalent.

Effect of terazosin hydrochloride combined with finasteride on serum TNF-αand PSA in elderly patients with benign prostatic hyperplasia / 中国生化药物杂志

Objective To explore the effect of terazosin hydrochloride combined with finasteride on serum TNF-αand PSA in old patients with benign prostatic hyperplasia.Methods 64 elderly patients of benign prostatic hyperplasia were randomly divided into 2 groups, 32 cases in each group.2 groups were given routine treatment and symptomatic treatment, the control group was given finasteride; the experimental group were treated with terazosin hydrochloride combined with finasteride.A cycle of 2 groups were 28 d, a total of 1 cycle of treatment.Clinical efficacy, maximum urinary flow rate, prostate volume, residual urine volume, international prostate symptom score(IPSS), serum tumor necrosis factor alpha, prostate specific antigen level and adverse reactions were compared after the end of treatment.Results Compared with before treatment, maximum urinary flow rate (Qmax) level of 2 groups increased, prostate volume, residual urine volume, international prostate symptom score(IPSS)decreased (P<0.05), compared with the control group, maximum urinary flow rate of the experimental group was higher (P<0.05), prostate volume, residual urine volume, IPSS were lower (P<0.05), 2 groups of TNF-αand PSA levels decreased after treatment (P<0.05), compared with the control group, TNF-αand PSA levels were lower(P<0.05).There was no significant difference in adverse reactions in 2 groups.Conclusion Terazosin hydrochloride combined with finasteride had a clinical efficacy of elderly patients with benign prostatic hyperplasia, can reduce serum TNF-αand PSA levels.

Terazosin as first line preoperative blockade in Filipino patients diagnosed with pheochromocytoma / Journal of the ASEAN Federation of Endocrine Societies

@#Pheochromocytoma, a rare cause of hypertension, is potentially fatal if left untreated. Definitive treatment is resection of the mass. Preoperative blockade is important to improve intraoperative hemodynamic stability and reduce morbidity during resection. Phenoxybenzamine, a non-selective alpha adrenergic blocker, has been widely used as preoperative blockade, but is unavailable in the Philippines. Terazosin, a selective alpha 1 antagonist and is widely available as treatment for benign prostatic hypertrophy, has been documented in reports as a suitable preoperative drug in reducing blood pressure in pheochromocytoma patients. The objective is to present four cases of Filipino pheochromocytoma patients who were treated with terazosin as first line preoperative blockade. Four Filipino patients from the Philippine General Hospital were diagnosed with pheochromocytoma based on biochemical and imaging studies. They were started on different doses of terazosin, the maximum dose as high as 4 mg per day. One patient experienced orthostatic hypotension at this dose, but was resolved after reducing the dose to 3 mg per day. A beta blocker (metoprolol on 3 cases, carvedilol) was added for reduction of the symptoms. One patient was also diagnosed with diabetic ketoacidosis, and was treated as such. Two patients experienced labile changes with blood pressure during resection but were resolved with the use of intravenous nicardipine for elevated blood pressure, and crystalloids during bouts of hypotension. All of the patients' blood pressure returned to normal after resection of the mass. Terazosin, a selective alpha 1 antagonist, at a maximum dose of 4 mg per day, may be safely given to Filipino patients diagnosed with pheochromocytoma as first line preoperative blockade.

Bioequivalence study on two terazosin hydrochloride tablets / 药学实践杂志

Objective To evaluate the bioequivalence of domestic and imported terazosin hydrochloride tablets after single oral dose .Methods It was a single center ,randomized ,open ,cross-over trail design ,21 subjects were fasting oral adminis-tered of 2 mg domestic and imported terazosin hydrochloride tablets in different periods ,venous blood 4 ml were collected in different time points before and 60 h after administration ,plasma concentration of terazosin was determined by LC-MS/MS . Results The main pharmacokinetic parameters of domestic and imported terazosin hydrochloride tablets were as follows :t1/2 :(13.2± 2.39)hvs(12.5±1.93)h,tmax :(1.01±0.83)hvs(1.08±0.69)h,Cmax :(40.1±10.6)ng/mlvs(37.3± 9 .57) ng/ml;AUC0- ∞ :(428 ± 82 .1) ng · h/ml vs (426 ± 85 .2) ng · h/ml .The relative bioavailability of domestic terazosin hydrochloride tablets was (101 .2 ± 14 .7)% .90% CI of domestic and imported terazosin hydrochloride tablets AUC0-t and Cmax geometric mean ratio fell between 80% -125% .Conclusion The domestic tablets are bioequivalent to the imported tablets .

Dissolution Comparison of Terazosin Hydrochloride Tablets and Capsules from Different Manufacturers / 中国药师

Objective:To compare the dissolution of domestic terazosin hydrochloride tablets and capsules to provide reference for clinical use. Methods:The dissolution of the products from different manufacturers was investigated respectively in 4 kinds of media:pH 1. 0 hydrochloric acid solution,pH 4. 5 phosphate buffer solution,pH 6. 8 phosphate buffer solution and water. The dissolution tests were carried out by a paddle method at the stirring speed of 50 r·min-1 and an HPLC method was used to determine the dissolution rate. The dissolution behavior of the samples from different manufacturers was compared by a similar factor method. Results:The do-mestic tablets showed higher similarity with the reference formula, and the dissolution behavior of the capsules had significant differ-ence. Conclusion:The calculation method for the specification in some manufacturers is different from that of the reference prepara-tion, which leads to the difference between the testing preparation and the reference preparation, and should be paid attention in clini-cal use.

Therapeutic effect and safety of amlodipine combined terazosin on middle and old aged male patients with essential hypertension / 心血管康复医学杂志

Objective:To observe the short-term therapeutic effect and safety of amlodipine combined terazosin on middle and old aged male patients with essential hypertension (EH).Methods:A total of 64 middle and old aged male EH patients treated in our hospital from Jan 2011 to Feb 2012 were enrolled.They were randomly and equally divided into amlodipine group and combined therapy group (received amlodipine combined terazosin treatment).Re-sults:Total effective rate of combined therapy group (93.75%)was significantly higher than that of amlodipine group (65.63%),P =0.028;there were significant reductions in levels of systolic blood pressure (SBP),diastolic blood pressure (DBP),total cholesterol (TC),triglyceride (TG)and fasting plasma glucose (FPG)in both groups after treatment (P <0.05~<0.01),compared with amlodipine group,there were more significant reductions in these indexes [SBP:(138.55±7.96)mmHg vs.(110.65±7.28)mmHg,DBP:(93.35±5.86)mmHg vs.(80.11 ±5.93)mmHg,TC:(5.67±0.76)mmol/L vs.(4.22±0.63)mmol/L,TG:(2.67±0.86)mmol/L vs.(2.01± 0.75)mmol/L,FBG: (5.69±0.86)mmol/L vs.(4.31±0.58)mmol/L]in combined therapy group,P <0.05 all;incidence rate of adverse reactions in combined therapy group (6.25%)was significantly lower than that of am-lodipine group (18.75%),P <0.05. Conclusion:Amlodipine combined terazosin possesses more therapeutic effect in middle and old aged male patients with essential hypertension.It can effectively reduce systolic and diastolic blood pressure;the adverse reactions are fewer,so it's worth extending in clinic.

Effect of terazosin on expressions of matrix metalloproteinase-9 and monocyte chemotactic protein 1 in a rat model of atherosclerosis / 实用医学杂志

Objective To investigate the effects of terazosin on expressions of matrix metalloproteinase-9 (MMP-9) and monocyte chemotactic protein 1 (MCP-1) in a rat model of atherosclerosis and to explore the mecha-nism for reducing atherosclerosis by terazosin. Methods Normal rats were fed with high lipid feedstuff to set up a rat model of atherosclerosis. Blood lipid indexes were measured and the expressions of MMP-9 and MCP-1 in aorta were detected and further quantified by immunohistochemistry after 12-week high lipid feedstuff. Results The plasma concentration of TG, TC, LDL in the terazosin group were significantly lower than those in the high cholesterol-diet group (P<0.01). The expressions of MMP-9 and MCP-1 in the high cholesterol-diet group and in the terazosin group were significantly higher than those in the normal-diet group (P < 0.01), but expressions of MMP-9 and MCP-1 in the terazosin group were significantly lower than those in the high cholesterol-diet group (P<0.01). Conclusion Terazosin can lower the concentration of TC, LDL but increase the HDL concentration. The anti-atherosclerotic mechanism of terazosin is associated with the decrease of the expressions of MMP-9 and MCP-1 and plasma lipoprotein.

Clinical application of terazosin combined with Qianlielongbitong in the treatment of chronic non-bacterial prostatitis / 中国基层医药

Objective To investigate the effect and mechanism of terazosin combined with Qianlielongbitong in the treatment of non-bacterial prostatitis.Methods One hundred and two patients with non-bacterial prostatitis were divided into two groups:one group was treated with terazosin 4 mg qn and Qianlielongbitong,while the other group was treated with terazosin and Levoofloxacin.We compared three indices of chronic prostatitis symptom index (NIH-CPSI),prostatic secretion examination(EPS) and urodynamic data in three different steps:before treatment,after 4-week treatment and after 8-week treatment.Results The NIH-CPSI of both groups was greatly improved after treatment( all P ＜0.01 ).Inside the treatment group,the NIH-C-PSI after 8-week treatment was better than that after 4- week treatment ( all P ＜ 0.01 ).However,in both groups,there was no significant difference between the index after 8-week treatment and the one after 4 week.EPS,AFR and MFR were greatly improved in both groups( all P ＜0.01 ).Conclusion Terazosin can relieve the clinical symptom,and improve the life quality.

Clinical study on the effectiveness and safety of terazosin in the treatment of benign prostatic hyperplasia patients with concomitant hypertension / 中国综合临床

Objective To evaluate the effectiveness and safety of terazosin in the treatment of benign prostatic hyperplasia (BPH)patients with concomitant hypertension.Methods A singlecenter prospective clinical observational study was conducted from March,2006 to March,2010 in our center.The main endpoints were the changes of IPSS total score,diastolic and systolic blood pressures at the end of 4 weeks and 3 monthes compared with the baseline,The second endpoints were Qmax value at the end of 4 weeks and 3 monthes compared with the baseline,Safety was assessed by adverse events.Results There were 212 patients in the study recruited,and 189 patients completed the study.All patients had BPH combined with hepertension.All patients were randomly devided into two statistical analysis group,blood pressure well controled and not well controled group,In the well controlled group,the IPSS socre reduced from 22.31 ± 5.18 at baseline to 15.64 ±3.91 at the end of the 4th weeks and 13.16 ± 3.53 at the end of 3rd monthes in the blood pressure well controled group populatin( P ＜ 0.01 ).The Qmax were improved significantly from (7.87 ± 2.41 ) ％ at baseline to (14.19 ±2.64)％ at the end of the 4th weeks and (15.69 ±2.77)％ at the end of3rd monthes in the blood pressure well controled group populatin( P ＜ 0.01 ).Terazosin had moderate effect in blood pressure decreasing (P ＜ 0.05 ),and all patients were within normal blood pressure range.In the uncontrolled group,the IPSS socre reduced from 21.55 ± 4.82 at baseline to 15.44 ± 3.66 at the end of the 4th weeks and 12.96 ± 3.11 at the end of 3rd monthes in the blood pressure well controled group populatin (P ＜ 0.01 ).The Qmax were improved significantly from ( 8.27 ± 2.27 ) ％ at baseline to ( 14.26 ± 2.87) ％ at the end of the 4th weeks and ( 15.51 ±2.92) ％ at the end of 3rd monthes in the blood pressure well controled group populatin( P ＜ 0.01 ).Terazosin decreased BPH patient blood pressure with controlled patients and unctrolled patients additionaly to other blood pressure medicine (P ＜ 0.05 ),and no severe side effect occured.At the end of the study,all patients were taking drug continuously and were followed.Conclnsion Terazosin can significantly improve the symptoms and quality of life in BPH patients with hypertension with good safety and compliance.

The Efficacy of Prostatic Massage Combined with α1 Receptor Blocker in the Treatment of Type Ⅲ Prostatitis / 中国基层医药

Objective To observe the efficacy of prostatic massage combined with α1 receptor blocker in the treatment of type Ⅲ prostatitis. Methods 86 cases were randomly divided into two groups. The treatment group( n =45 ) were given twice-weekly prostatic massage in combination with α1 receptor blocker( terazosin 2mg per night) for 6 weeks. Thc control group(n =41 )were only given terazosin 2mg per night for 6 weeks. AII the patients were asked to complete the National Institutes of Healthe Chronic Prostatitis Symptom Index(NIH-CPSI) before and after the treatment. Results 86 cases were evaluated after the treatment. The NIH-CPSI scores of the two groups decreased from ( 29.5 ± 4.2 ) to ( 9.6 ± 3.8), from ( 28.9 ± 3.4) to ( 14.6 ± 3.6) respectively, with statistically significant differences from pretreatment( t = 12.131、6.999, all P ＜ 0.05 )as well as between the combined therapy group and the control group(t = 4.649, P ＜ 0.05). There were no serious side effects during the therapy. Conclusion Prostatic massage combined with α1 receptor blocker can relieve the symptoms in type Ⅲ prostatitis patients and improve their life quality. The combined therapy can produce better efficacy than terazosin used alone.

Terazosin treatment in BPH/LUTS: a prospective, randomized, multicenter study / 中华泌尿外科杂志

Objective To compare the efficacy and safety of 2 mg/d and 4 mg/d of terazosin in the treatment of benign prostatic hyperplasia (BPH) with lower urinary tract symptoms (LUTS).Methods A total of 120 BPH patients were randomly divided into 2 groups receiving 2 mg or 4 mg terazosin per day for 2 months. Arterial blood pressure, International Prostatic Symptom Score (IPSS) and peak flow rate (Qmax) before and after treatment were compared while side effects were estimated. Results Forty-six patients receiving 2 mg and 54 patients receiving 4 mg terazosin completed this study. Patients' age and pre-treatment blood pressure, IPSS and Qmax had no difference between the 2 groups. The improvement of IPSS (including obstructive score, irritating score and total IPSS) and Qmax was significantly better in 4 mg group. The percentage of patients experiencing greater than 30% improvement in Qmax in the 4 mg treatment groups was significantly higher than that of the 2 mg group (46.3% vs 23.9%, P=0.02). Side effects were rare and mild in both groups.Conclusion The improvements of IPSS and Qmax are significantly greater in 4 mg treatment of terazosin than that of 2 mg with no obvious increase of side effects.

A multicenter prospective clinical study on the effectiveness and safety of terazosin in the treatment of Chinese benign prostatic hyperplasia patients / 中华泌尿外科杂志

Objective To evaluate the effectiveness and safety of terazosin in the treatment of Chinese benign prostatic hyperplasia (BPH) patients. Methods A multicenter prospective postmarketing observational study was conducted from June 2007 to March 2008 in 32 urologic centers.Patients were given terazosin for 4 weeks according to the routine medical care procedures following instructions. Effectiveness evaluation included the primary endpoint focusing on the changes in IPSS total score at the end of 2nd and 4th week compared with the baseline. The secondary endpoints were the changes in Qmax and QOL at the end of 4th week, diastolic and systolic blood pressures at the end of 2nd and 4th week compared with the baseline and the discontinuation rate of terazosin within the four weeks. Safety was assessed by adverse events. Results There were 1006 patients included in this study (FAS) and 992 patients (PP) completed the study. Among them, there were 344 patients having hypertension. The total IPSS score reduced from 22.32±6. 13 at baseline to 16. 98±5.92 at the end of the 2nd week and to 14.00±5. 52 at the end of the 4th week in FAS population (P＜0. 01).The total IPSS score changed from 22.32±6.15 at baseline to 16. 96±5.93 at the end of the 2nd week and to 13. 95±5.52 at the end of the 4th week in the PP population (P＜0.01). The efficacy rate was 26.54% at the 2-week treatment and 60.64% at the 4-week treatment, which was defined as obtaining improvement by 30% compared with the baseline. Patient's IPSS in different age groups with different prostatic hyperplasia levels and patients combined with or without 5-α reductase inhibitors were all decreased significantly(P＜0.01). With 4-week treatment of terazosin, Qmax and QOL were improved significantly by 32% and 45% (P＜0.01). Terazosin decreased BPH patient blood pressure with untreated or uncontrolled hypertension (P＜0.05), but had little influence on normal blood pressure of those under control. The incidence of adverse reactions was low. The most common adverse event was dizziness (3.68%). At the end of the study, 960 subjects (95%) were taking drug continuously.Conclasions Terazosin can significantly improve the symptoms and quality of life in Chinese BPH patients with good safety and compliance.

Combination of epristeride and terazosin for treatment of benign prostatic hyperplasia / 中国医师进修杂志

Objective To evaluate the security and efficacy of combination of epristeride and terazosin for treatment of benign prostatic hyperplasia (BPH). Method One hundred and eighty-four patients with BPH were treated by epristeride for 6 months and terazosin for 1 month, the efficacy and complication were observed. Results After 6 months treated, compared with before treated, the common symptoms improved, the residual urine decreased 20.74ml, maximum flow rate increased 3.76 ml/s, prostate volume grown downwards 6.70cm3 and the quality of life raised apparently(Pall＜0.05 ). Condusion Combinationof epristeride and terazosin for treatment of BPH is safe and effective.

High-Dose Terazosin Therapy (5mg) in Korean Patients with Lower Urinary Tract Symptoms with or without Concomitant Hypertension: A Prospective, Open-Label Study

PURPOSE: We determined the efficacy and safety of a relatively high dose of terazosin (5mg) in Korean patients with lower urinary tract symptoms (LUTS), with or without concomitant hypertension. MATERIALS AND METHODS: From July to December 2006, 200 men who consecutively presented with LUTS were prospectively studied. Eight weeks after treatment, blood pressure (BP), uroflowmetry, and International Prostate Symptom Score (I-PSS) were assessed. For analysis purposes, patients were stratified according to concomitant hypertension. Of the 200 patients, 173 completed the scheduled eight-week treatment period. RESULTS: At baseline, no differences were evident in the two groups in terms of I-PSS, Qmax, PVR and BP. After eight weeks of treatment-although I-PSS and uroflowmetry parameters were not significantly different in the two groups-systolic and diastolic BP in the non-hypertensive control group were higher than in the hypertensive group (p= 0.001 and p=0.0100, respectively). Changes in I-PSS, uroflowmetry parameters, and BPs measured at week eight post- treatment commencement did not significantly differ between the two groups. Moreover, the addition of 5mg of terazosin to antihypertensives did not cause a significant reduction in either systolic or diastolic BP in either group. CONCLUSION: Adding terazosin to existing antihypertensive regimens did not seem to increase the incidence of adverse events. Our findings suggest that 5mg terazosin is effective and that it has an acceptable safety profile as an add-on therapy for patients with LUTS and concomitant hypertension.

The Effect of Terazosin on the Histological Changes of Rat Bladder after Partial Outlet Obstruction

PURPOSE: When the bladder outlet is partially obstructed, The expression of iNOS and collagen type III is caused by ischemia of bladder. This study aimed to evaluate the hemodynamic changes and the expression of inducible nitric oxide synthase(iNOS) and collagen type III of bladder during acute stages of partial bladder outlet obstruction in female rats and conducted a research on the effect of alpha-adrenergic blocker. MATERIALS AND METHODS: Thirty mature Sprague-Dawley rats were randomly divided into three groups; 3 days(Group I), 7 days(Group II), 14 days(Group III), depending on the term of partial bladder outlet obstruction. After obstruction, each group was subdivided into the experimental groups and the control groups; terazosin(0.4 mg/kg) was administered to the experimental groups and normal saline was administered to the control groups for a week. The degree of expression of iNOS and collagen type III in bladder was investigated by immunohistochemical stain and Western blot. RESULTS: The blood flow of experimental groups showed significant increase compared to control groups(p<0.05). The expression of iNOS and collagen type III of exerimental groups was significantly decreased compared to the controls(p<0.05). CONCLUSION: This study suggests that alpha-adrenergic blocker makes increase in blood flows to bladder and may have a role of prevention from functional damage of bladder.

The Efficacy of Terazosin in the Management of Chronic Pelvic Pain Syndrome (CPPS): Comparison between Category IIIa and IIIb / 대한비뇨기과학회지

Purpose: To evaluate the efficacy of terazosin in chronic pelvic pain syndrome (CPPS) and compare the effect of terazosin between CPPS IIIa and IIIb. Materials end Methods: Between January 2004 and February 2005, CPPS patients, aged 45 or below, with a small size prostate (0.05). In category IIIb (n=56), the T group (n=29) showed significant improvements in all NIH-CPSI domains and the Qmax (p0.05). Comparing both category IIIb groups, the T group showed a greater improvement in the pain score in the NIH-CPSI domains and the Qmax than the non-T group. Conclusions: Terazosin was effective in all domains of the symptom score and in the Qmax for CPPS.

Efficacy and Safety of Combination Therapy with Amlodipine Plus Terazosin in Patients with Essential Hypertension / 中华高血压杂志

Objective To evaluate the short-term efficacy and safety of combination therapy with amlodipine and terazosin in middle aged and old male patients with essential hypertension.Methods Randomized,prospective,parallel study was carried out in middle aged and old male patients with essential hypertension in Anqing community between August 2005 and February 2006.Antihypertensive efficacy and safety of the combination therapy were evaluated in 508 patient who completed the study.Results After 4 weeks treatment,the average reduction of SBP were 4.0?15.0,17.5?15.8 and 20.0?15.9 mm Hg in Terazosin group,amlodipine group and combination group,respectively(P

The comparison between diclofenac sodium suppository and terazosin in treatment of prostatodynia / 中国基层医药

Objective To compare the clinical efficacy of diciofenac sodium suppository and terazosin in treatment of prostatodynia. Methods 120 patients(age ranging from 19 to 48 years,mean age was 29. 8 years) suffering from prostatodynia, were randomly divided into 2 groups: diciofenac sudium suppositoy group of 60 patients (50mg,rectal medication, q12h for 2 weeks) and terazosin group of 60 patients (2mg, per os, q12h or qn for 2 weeks).The therapeutic effects and side-effects were compared after 2 weeks treatment. Results The total clinical effective rate in diciofenac sudium suppository group was 97% , higher than that (80%) of terazosin groups(P